Trends & Forecasts

President Trump has the opportunity to get healthcare moving by boosting biogeneric use.

Bribery accusations, a new whistleblowing policy, and recalls... What’s new for pharma in business?

Celebrating the great and good of drug development: welcome to The Medicine Maker 2017 Power List

Should the UK National Health Service manufacture some generic drugs?

Marathon sells Emflaza, but questions remain about FDA approval processes.

Pharma has a number of underlying structural issues. It's time for a change of direction.

India has held pharma’s interest for decades, but it is a challening market to work in.

It's time to develop an ethical code for the pharmaceutical industry.

Today, the majority of the contract manufacturing market is made up of small molecules.

Mark Paxton was appointed CEO of Rx-360 in 2015. Here, he discusses the journey so far